Next-Generation R&D Virtualization Strategies
(recorded on May 18, 2010)
Sponsored by: Oracle
Purchase DVD or Electronic Version
Program Description:
The biopharmaceutical industry is at a significant point in its evolution. Without doubt fundamental changes within industry processes are required. The principal force driving this need for change is the unprecedented number of market-leading drugs facing patent expirations. For the leading pharmaceutical companies between 14% and 41% of their existing revenues will be lost as a result of patent expiries. With so many blockbuster drugs going off patent the imperative for companies is to replace them with similar high-earning products in order to sustain both rising R&D costs and market and shareholder expectations. However, the shortage of suitable replacements in the pipeline together with declining productivity compounds the challenges faced by the biopharmaceutical industry.
Pharmaceutical R&D, under the traditional model, was generally performed within the walls of one single company or entity. With the increasing recognition that innovation arises from a wide variety of sources (and the interactions between these entities) this centralized hub model is gradually being transformed into a multi-hub, integrated, networked structure. Innovation is now accessed not only from within pharma but also from scientific or licensed partners; academic centers; and even from sources traditionally thought of as ’only’ service providers, such as Clinical Research Organizations (CROs). The definition of the virtualization of R&D is essentially an externalization of the core processes that make up this wide area. The multi-tiered network of innovation traverses across multiple entities – commercial and academic – to achieve a coordinated research or development goal. Rather than conduct all the core activities in one physical place – confining creativity – the new model is an exciting kinetic network of research centers, or skill centers, together with a global network of clinical development sites.
DVD or Electronic Version Price: $295 each
Key Learning Objectives:
Who Should Attend:
Scientitsts and researchers involved in research and development
Professionals responsible for managing scientific and clinical information
Executives seeking better time and cost ROI in R&D
Speakers:
Kate Moss, Director, European Pharmaceutical & Life Sciences, Advisory Services, Pricewaterhouse Coopers (UK)
Chris Dagdigian, Founder & Director of Technology, The BioTeam
Purchase DVD or Electronic Version